Compare Crispr Therapeutics AG (CRSP) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vertiv Holdings Co — how do they compare? Crispr Therapeutics AG trades at $53.99 (market cap $5.17B), while Vertiv Holdings Co trades at $284.64 (market cap $103.99B). The key difference: Vertiv Holdings Co is far larger — about 20.1× Crispr Therapeutics AG's market cap, and Vertiv Holdings Co pays a 0.09% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | VRT | |
|---|---|---|
Market Cap | $5.17B | $103.99B |
Sector | Health | Technology |
52-Week High | $76.78 | $376.23 |
52-Week Low | $44.34 | $121.82 |
Enterprise Value | $3.59B | $104.21B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
VRT trades at $272.40, down 1.01% on the day, with a bearish technical signal driven by moving averages and RSI levels near overbought territory. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.52 versus $1.43 expected, and revenue growth is supported by AI data center demand. Recent news highlights its role in AI infrastructure, though legal investigations pose a sentiment risk.
Outlook remains positive with a consensus price target of $386.58, reflecting 42% upside, driven by robust fundamentals and AI tailwinds. Risks include high valuation multiples, competitive pressures, and ongoing legal scrutiny. Investors should weigh growth potential against elevated P/E and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
